慢性胃炎应用奥美拉唑、正气散加减方联合治疗对细胞炎性因子和胃蛋白酶PG、GS影响探讨  

Observation on the Effects of Zhengqi San(正气散)Combined with Omeprazole on Cytokines and Pepsinogen,Gastrin in Chronic Gastritis Patients

作　　者：周慧 周昕欣[2] 曲颂扬[1] ZHOU Hui;ZHOU Xinxin;QU Songyang(Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,Liaoning,China;Liaoning University of Traditional Chinese Medicine,Shenyang 110847,Liaoning,China)

机构地区：[1]辽宁中医药大学附属医院,辽宁沈阳110032 [2]辽宁中医药大学,辽宁沈阳110847

出　　处：《辽宁中医药大学学报》2022年第2期80-83,共4页Journal of Liaoning University of Traditional Chinese Medicine

基　　金：国家自然科学基金(81803849)。

摘　　要：目的探索正气散加减方联合奥美拉唑与仅使用奥美拉唑治疗耐慢性胃炎的临床对比研究。方法选取2016年2月—2017年4月在医院收治的慢性胃炎患者83例。慢性胃炎患者被归类为仅使用奥美拉唑治疗组(单一组):慢性胃炎41例患者采取奥美拉唑方案治疗;正气散加减方联合奥美拉唑治疗组(联合组):慢性胃炎42例患者在单一组患者基础上结合正气散加减方方案治疗。比较联合组与单一组患者的中医证候评分、临床疗效、细胞炎性因子以及胃蛋白酶水平。结果(1)经过治疗后发现正气散加减方结合奥美拉唑组中医证候评分(3.05±1.16)分对比奥美拉唑组(5.98±1.58)分明显较低(P<0.05)。(2)经过治疗后发现正气散加减方结合奥美拉唑组临床疗效总有效率92.85%对比奥美拉唑组80.48%明显较高(P<0.05)。(3)经过治疗后发现正气散加减方结合奥美拉唑组细胞炎性因子IL-6(20.13±7.96)ng/mL、TNF-α(1.06±0.49)μg/L水平对比奥美拉唑组IL-6(35.38±10.04)ng/mL、TNF-α(1.95±0.62)μg/L水平具有明显优势(P<0.05)。(4)经过治疗后发现正气散加减方结合奥美拉唑组胃蛋白酶PG(120.49±29.21)μg/L、GS(7.48±2.01)pmol/L水平对比奥美拉唑组PG(103.61±29.66)μg/L、GS(4.59±3.74)pmol/L水平具有明显优势(P<0.05)。结论采用正气散加减方联合奥美拉唑方案治疗慢性胃炎效果确切,对比中医证候评分、临床疗效、细胞炎性因子以及胃蛋白酶水平等方面具有明显的优势,关于治疗后的长期效果该研究未进行深入与进一步探讨,存在一些不足,在此处有待改进。Objective To observe the effect of Zhengqi San(正气散)combined with omeprazole and single omeprazole for the treatment of chronic gastritis patients.Methods From February 2016 to April 2017,83 patients with chronic gastritis were analyzed retrospectively in our hospital.The patients were classified as omeprazole group(single group):41 patients were treated with omeprazole regimen alone;Zhengqi San combined with omeprazole group(combined group):42 patients were treated with Zhengqi San combined with omeprazole regimen.The TCM certificate rating,clinical efficacy,cytophilis factors and gastric protease levels were compared between groups.Results(1)After treatment,it was found that the TCM syndrome score of modified Zhengqi San combined with omeprazole group(3.0±1.16)points was significantly lower than that of omeprazole group(5.98±1.58)points,P<0.05.(2)After treatment,it was found that the total effective rate of the modified Zhengqi San combined with omeprazole group was 92.85%,which was significantly higher than that of the omeprazole group 80.48%,P<0.05.(3)After treatment,it was found that the levels of IL-6(20.13±7.96)ng/mL and TNF-α(1.06±0.49)μg/L in the modified Zhengqi San combined with omeprazole group were significantly higher than those in the omeprazole group(35.38±10.04)ng/mL and TNF-α(1.95±0.62)μg/L,P<0.05.(4)After treatment,it was found that the levels of pepsinogen(PG,120.49±29.21)μg/L and gastrin(GS,7.48±2.01)pmol/L in the modified Zhengqi San combined with omeprazole group were significantly higher than those in the omeprazole group(103.61±29.66)μg/L and(4.59±3.74)pmol/L,P<0.05.Conclusion For the treatment of chronic gastritis,the effect of Zhengqi San combined with omeprazole is accurate,and there are obvious advantages in the TCM certificate rating,clinical efficacy,cytophilis factors and gastric protease levels.The long-term effect does not carry out in this study.There are some shortcomings and need to be improved.

关 键 词：正气散 奥美拉唑 慢性胃炎 中医证候评分 细胞炎性因子 胃蛋白酶水平 

分 类 号：R573.3[医药卫生—消化系统]